C. parvum clinical protocols: prototypes and summary results in U. S. trials with Wellcome Coparvax.
Clinical investigations utilizing Wellcome C. parvum in cancer therapy number more than one hundred in multiple institutions. Multiple diseases in various stages are being attacked by multi-modality therapy, making the role of immunotherapy very difficult to assess. Fundamental laboratory observations have suggested ways of weaving non-specific with specific immunotherapy, and these with chemotherapy and radiation to yield maximum therapeutic benefit. Current protocols include examples of the critical interactions as well as instructive information on dosing, timing and adjunctive symptomatic therapies. Several protocols will be reviewed, especially where promising clinical results are expected. Important differences between systemic and regional administration are observed.
D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D007263:Infusions, Parenteral; D009369:Neoplasms / Q000628:therapy*; D011425:Propionibacterium acnes